NCT07473713RecruitingPhase 1
Veverimer to Decrease Net Acid Excretion and Bone Resorption in Adults With Osteopenia: a Dose-finding Randomized Controlled Trial
Interventions
Trial Snapshot
- Phase
- Phase 1
- Status
- Recruiting
- Sponsor
- Tufts Medical Center
- Enrollment
- 60
- Locations
- 1
- Primary Endpoint
- 24-hr urinary net acid excretion
Study Overview
Brief Summary
The goal of this clinical trial is to learn if veverimer will reduce urinary net acid excretion leading to reduced bone resorption in healthy adults with osteopenia. The main questions it aims to answer are:
- How much does each dose of veverimer (vs. placebo) reduce 24-hr urinary net acid excretion.
- Describe the safety of veverimer based on changes in serum bicarbonate and potassium.
- Assess the changes in bone resorption.
- Assess the changes in bone formation.
- Explore the effect of veverimer on physical performance.
Participants will:
- Take veverimer or placebo every day or every other day for 8 weeks
- Visit the clinic a total of 8 times (including screening) for checkups and testing
- Keep a medication diary tracking each day they take the study drug
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Prevention
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 50 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Community dwelling adults age 50 years and older (approximately equal numbers of men and women).
- •Men should be sterile or agree to use contraception throughout the study.
- •Women must be postmenopausal, defined as no menses in the last 5 years (to reduce variability in change in bone resorption since menopause prompts a rapid increase in bone resorption).
- •Osteopenia will be defined as a bone mineral density (BMD) T-score at the lumbar spine, femoral neck, or total hip lower than -1 or higher than -2.
- •On a prescreening interview, candidates must report a usual diet associated with an acid load by our validated short questionnaire.
- •Estimated glomerular filtration rate (eGFR) must be 45 ml/min or greater.
- •Participants must agree not to change their exercise pattern or medication use during the study.
- •Participants must agree not to change their pattern of supplement use and not to use antacids during the study because most calcium supplements and other antacids add alkali.
- •Participants must agree to not change their eating habits or intentionally change their weight.
Exclusion Criteria
- •Normal BMD T-scores at all spine and hip sites, osteoporosis based on BMD T-score of -2.5 or less
- •Respiratory illness in last month
- •Chronic obstructive pulmonary disease (COPD)
- •Nausea/vomiting in last month
- •Malabsorption
- •Inflammatory bowel disease
- •Chronic diarrhea (defined as loose bowel movements daily) or constipation (≤ 2 stools per week)
- •Insulin-requiring diabetes or fasting plasma glucose >125 mg/dl
- •Untreated thyroid disease
- •Current unstable heart disease
- •Malignancy (except non-melanoma skin cancer) or cancer therapy in last year
- •Alcohol use >2 drinks/day.
- •Individuals who are unable to provide informed consent due to cognitive impairment.
Arms & Interventions
Placebo (microcrystalline cellulose with 0.075% yellow ferric oxide)
Placebo Comparator
Intervention: Placebo (Other)
Veverimer 9 g/day
Experimental
Intervention: veverimer daily (Drug)
Veverimer 9 g/every other day
Experimental
Intervention: veverimer every other day (Drug)
Outcomes
Primary Outcomes
24-hr urinary net acid excretion
Time Frame: measured at screening, week 2, week 8 and week 8 +1day
Secondary Outcomes
- Serum bicarbonate level(measured at screening, week 0, week 1, week 2, week 4, week 8)
- Serum potassium level(measured at screening, week 0, week 1, week 2, week 4, week 8)
- Serum C-telopeptide level(measured at week 0, week 2, week 8)
- Serum procollagen type 1 N-propeptide level(measured at week 0 and week 8)
Investigators
Study Sites (1)
Loading locations...
Similar Trials
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic AcidosisCKDNCT07355062Renibus Therapeutics, Inc.150
Not yet recruiting
Phase 3 4
Effect of Vaitrain Basti and Anuvasana Basti With Ashtkatwar Taila in the Management Of SciaticaCTRI/2024/09/074159Dr Sarvapalli Radhakrishnan Rajasthan Ayurved University Kadwar Jodhpur Rajasthan60
Recruiting
Phase 2
Double-blind, placebo-controlled clinical trial to determine the effect of Patiromer on vascular function and its relationship with mineral metabolism parameters2023-503941-69-00Fundacion Para La Investigacion Biomedica De Cordoba40
Not yet recruiting
Phase 2
Comparison between intravenous Calcium Chloride vs only Oxytocin in decreasing blood loss during cesarean deliveryCTRI/2025/07/090730Varsha Rani66
Recruiting
Phase 4
A study on effect of metabolic acidosis correction on progression of CKDCTRI/2024/11/076264Jawaharlal Institute of postgraduate medical education and research126